Effect of Race and Hypertension on Plasma Amylin Concentrations
- 1 June 1996
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Hypertension
- Vol. 27 (6) , 1273-1276
- https://doi.org/10.1161/01.hyp.27.6.1273
Abstract
Abstract Amylin is a recently discovered peptide hormone composed of 37 amino acids that is cosecreted with insulin by pancreatic β cells. Amylin has been reported to be present in increased amounts in insulin-resistant subjects who are hyperinsulinemic. Because blacks and whites differ in the prevalence of both hypertension and diabetes, we examined amylin levels in 77 individuals; 42 were black (11 hypertensive and 31 normotensive) and 35 were white (10 hypertensive and 25 normotensive) individuals who were either healthy control subjects or hypertensive subjects not receiving antihypertensive medication. Plasma amylin concentrations were measured in two separate monoclonal antibody–based immunofluorescent sandwich-type assays. The F002-2 capture antibody binds amylin plus at least two additional amylin-like peptides, and the F024-4 capture antibody detectably binds only the amylin peptide. There was a significant race-by-diagnosis interaction for levels of amylin immunoreactivity during a 2-hour glucose tolerance test ( P <.005 for F002-2 antibody and P <.05 for F024-4 antibody). Highest levels were found in black hypertensive subjects. The results appear to fit with previously observed differences in metabolic status between blacks and whites and with the association between hypertension and alterations in metabolic status.Keywords
This publication has 15 references indexed in Scilit:
- Insulin resistance: the shape of things to comeThe Lancet, 1994
- Amylin and Syndrome‐XDrug Development Research, 1994
- Racial Differences in the Relation between Blood Pressure and Insulin ResistanceNew England Journal of Medicine, 1991
- Inhibition of insulin release by amylin is not mediated by changes in somatostatin outputLife Sciences, 1991
- The relationships of concentrations of insulin, intact proinsulin and 32?33 split proinsulin with cardiovascular risk factors in Type 2 (non-insulin-dependent) diabetic subjectsDiabetologia, 1990
- Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients.Proceedings of the National Academy of Sciences, 1987
- Insulin Resistance in Essential HypertensionNew England Journal of Medicine, 1987
- Insulin Infusion in Conscious DogsJournal of Clinical Investigation, 1982
- Effect of Insulin and Glucose Infusions on Sympathetic Nervous System Activity in Normal ManDiabetes, 1981
- SERUM-INSULIN IN ESSENTIAL HYPERTENSION AND IN PERIPHERAL VASCULAR DISEASEThe Lancet, 1966